Pietrogrande L, Raimondo E
University of Milan, Health Sciences Department, Milan, Italy.
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, Unità Operativa di Ortopedia e Traumatologia, Milan, Italy.
Drugs Today (Barc). 2018 May;54(5):293-303. doi: 10.1358/dot.2018.54.5.2800621.
Abaloparatide is a synthetic 34-amino acid peptide analogue of the 1-34 portion of the human parathyroid hormone-related protein (PTHrP). It has been approved in the U.S. for the treatment of postmenopausal women with osteoporosis at a high risk for fracture. Abaloparatide is an anabolic agent and it seems to have a potent anabolic activity with reduced effects on bone resorption. It reduces the risk of vertebral and nonvertebral fractures, major osteoporotic fractures and clinical fractures, with a significant improvement in bone mineral density at femoral neck, total hip and lumbar spine. In this article we summarize the development of the abaloparatide molecule and preclinical and clinical studies published so far. Results from clinical trials indicate that abaloparatide may become an important option for the anabolic treatment of postmenopausal osteoporosis.
阿巴洛肽是一种合成的34个氨基酸的肽类似物，其结构与人甲状旁腺激素相关蛋白（PTHrP）的1-34部分相似。它已在美国获批用于治疗具有高骨折风险的绝经后骨质疏松症女性。阿巴洛肽是一种促合成代谢药物，似乎具有强大的促合成代谢活性，同时对骨吸收的影响较小。它可降低椎体和非椎体骨折、主要骨质疏松性骨折和临床骨折的风险，并显著提高股骨颈、全髋和腰椎的骨矿物质密度。在本文中，我们总结了阿巴洛肽分子的研发情况以及迄今为止发表的临床前和临床研究。临床试验结果表明，阿巴洛肽可能成为绝经后骨质疏松症促合成代谢治疗的重要选择。
